MedPath

A phase II trial of conversion surgery after induction chemotherapy(Gemcitabine+nab-Paclitaxel) and chemoradiotherapy(RT+S-1) for the patients with locally advanced pancreatic cancer.

Phase 2
Conditions
Pancreatic cancer
Registration Number
JPRN-UMIN000023217
Lead Sponsor
Ochanomizu Gastrointestinal Oncology Group
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
11
Inclusion Criteria

Not provided

Exclusion Criteria

1)-1 Initially diagnosed as resectable pancreatic cancer -2 Initially diagnosed as unresectable pancreatic cancer with distant metastasis 2)Age: over 80 years, or less than 20 years 3)ECOG performance status =>2 4)Previous treatments 5)Labodata do not satisfy inclusion criteria 6)No written informed consent 7)Inadequate physical condition, as diagnosed by primary physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The R0 resection rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath